Jared Louis Wolff
Analyst
Jared Wolff is an Analyst at CBPartners.
Connect with Jared Louis Wolff
Published Articles
July 6, 2020 | Blog
What’s Next for Alzheimer’s Disease?
Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed
May 26, 2020 | Podcasts
COVID-19 (Pt 3): Testing
The final episode of the COVID-19 trilogy focuses on testing. Specifically, the different types of tests available for COVID-19 and the regulatory environment in which these tests exist.
May 7, 2020 | Podcasts
CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?
Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.
April 21, 2020 | Podcasts
CBPartners’ Pharma Take-Away: COVID-19 (Pt 2): Promising Treatments in Development
In Part 2 of the COVID-19 series, healthcare consultant Jared Wolff is again joined by Matthew Rube and Akhil Parlapalli from CBPartners’ New York office to discuss some of the most promising treatments that are currently being put to the test against COVID-19.
March 26, 2020 | Podcasts
CBPartners’ Pharma Take-Away: Cell and Gene Therapy Roundtable
In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.
March 17, 2020 | Podcasts
CBPartners’ Pharma Take-Away: COVID-19 (Pt 1): Roundtable
In this episode, Jared Wolff is joined by Matthew Rube and Akhil Parlapalli from CBPartners' New York office to discuss some of the topics surrounding the novel coronavirus (COVID-19) pandemic: